Zoetis Inc. develops, manufactures, and sells medication for pets and livestock. On the company's 2023 balance sheet, under finite-lived intangible assets, the company reported having $885 million in "Developed technology rights." According to the company: Developed technology rights represent the amortized cost associated with developed technology, which has been acquired from third parties and which can include the right to develop, use, market, sell and/or offer for sale the product, compounds and intellectual property that we have acquired with respect to products, compounds and/or processes that have been completed. These assets include technologies related to the care and treatment of dogs, cats, horses, cattle, swine, poultry, fish and sheep. Developed technology rights are most likely to be what kind of finite-lived intangible asset